Join Growin Stock Community!

Okyo pharma limitedOKYO.US Overview

US StockHealthcare
(No presentation for OKYO)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

OKYO AI Insights

OKYO Overall Performance

OKYO AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

OKYO Recent Performance

1.17%

Okyo pharma limited

0.05%

Avg of Sector

-0.31%

S&P500

OKYO PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

OKYO Key Information

OKYO Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

OKYO Profile

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Price of OKYO

OKYO FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

OKYO Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.12
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
14.11
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
6.73%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
32.57%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.12
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
14.11
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
6.73%
3-Year Revenue Growth
-100.00%
3-Year Profit Growth
32.57%

  • When is OKYO's latest earnings report released?

    The most recent financial report for Okyo pharma limited (OKYO) covers the period of 2025Q4 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating OKYO's short-term business performance and financial health. For the latest updates on OKYO's earnings releases, visit this page regularly.

  • How much cash does OKYO have?

    At the end of the period, Okyo pharma limited (OKYO) held Total Cash and Cash Equivalents of 1.56M, accounting for 0.42 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is OKYO's EPS continuing to grow?

    According to the past four quarterly reports, Okyo pharma limited (OKYO)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.04. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of OKYO?

    Okyo pharma limited (OKYO)'s Free Cash Flow (FCF) for the period is -1.57M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 58,193.21% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.